 | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C34H33BrN6O3 |
| Molar mass | 653.581 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Deleobuvir (formerlyBI 207127) was an experimental drug for the treatment ofhepatitis C. It was beingdeveloped byBoehringer Ingelheim. It is a non-nucleosidehepatitis C virus NS5B polymerase inhibitor. Deleobuvir was tested in combination regimens withpegylated interferon andribavirin, and in interferon-free regimens with other direct-acting antiviral agents includingfaldaprevir.[citation needed]
Data from the SOUND-C2 study, presented at the 2012AASLD Liver Meeting, showed that a triple combination of deleobuvir,faldaprevir, andribavirin performed well in HCV genotype 1b patients.[1] Efficacy fell below 50%, however, for dual regimens without ribavirin and for genotype 1a patients.[citation needed]
These results were confirmed in the SOUND-C3 study, presented at the 2013 APASL Liver Conference, which found that 16-week triple therapy with deleobuvir +faldaprevir +ribavirin gave 95% SVR12 in HCV genotype 1b patients but poor virological response in genotype 1a.[2]
In December 2013, Boehringer Ingelheim announced that the development of deleobuvir would not be continued since recent findings from phase III trials did not suggest sufficient efficacy.[citation needed]
 | Thisantiinfectivedrug article is astub. You can help Wikipedia byexpanding it. |
